摘要 |
<p>The present invention relates to the identification and use of diagnostic markers related with brain damage, particularly, biomarkers independently selected from the group consisting of interleukin-17 (IL-17), Fas ligand (FasL), b nerve growth factor (bNGF), insulin growth factor binding protein 3 (IGFBP3), p55 tumour necrosis factor receptor (TNFR-1), growth-related oncogene alpha (GroA), interleukin-2 soluble receptor gamma (IL2RG) and combinations thereof, that are associated with the diagnosis, prognosis, or differentiation of stroke mimicking conditions and stroke in a subject.</p> |